Partnering with Providers
Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help inform treatment strategies for your advanced cancer patients. Discover in-depth genomic insights and a breadth of offerings to help you integrate comprehensive genomic profiling into your practice.
Comprehensive Genomic Profiling Tests
Discover tissue- and blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors where fusion detection is desired.
Online Ordering & Report Integrations
Foundation Medicine offers online ordering, digital reporting, and EMR and API integrations to help integrate comprehensive genomic profiling into your workflow.
Clinical Research & Trial Matching
Leverage our molecular information through our clinical research and trial matching services to help inform treatment decisions for your patients.
Decision Support & Provider Education
From interpretation of results on each report to expert consultations and ongoing education, we can help you make the most of comprehensive genomic profiling (CGP) in your practice.
Foundation Facts & Figures
Foundation Medicine has the most experience with comprehensive genomic profiling in the industry.*
Patient Samples Profiled
FoundationOne®Liquid CDx has been approved by the FDA as the only blood-based CGP companion diagnostic (CDx) for Tabrecta® (capmatinib). Our FDA-approved portfolio of both CGP tissue- and blood-based tests are now approved as the only CDx for Tabrecta® (capmatinib) in identifying advanced non-small cell lung cancer (NSCLC) patients having mutations that lead to METex14 skipping mutations and offers the highest number of CDx indications in NSCLC.
Our FoundationOne CDx tissue-based test has been approved as the only FDA-approved companion diagnostic to detect NTRK1/2/3 fusions for Vitrakvi® (larotrectinib).
* As defined by the number of cancer patients tested by Foundation Medicine in a clinical setting with comprehensive genomic profiling and the amount of evidence published by Foundation Medicine in a research setting about comprehensive genomic profiling.
Important Safety Information
FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.
FoundationOne Liquid CDx
FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.